541304 — Indo US Bio-Tech Income Statement
0.000.00%
Last trade - 00:00
- IN₹4.71bn
- IN₹4.86bn
- IN₹617.45m
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 353 | 398 | 401 | 501 | 617 |
Cost of Revenue | |||||
Gross Profit | 77.6 | 79.2 | 148 | 139 | 166 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 321 | 360 | 348 | 438 | 532 |
Operating Profit | 32.2 | 37.5 | 52.6 | 63 | 85.5 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 28.1 | 28.6 | 41.3 | 53.1 | 73.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | 20.9 | 25.3 | 51 | 50.6 | 72.4 |
Net Income Before Extraordinary Items | |||||
Net Income | 20.9 | 25.3 | 51 | 50.6 | 72.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 20.9 | 25.3 | 51 | 50.6 | 72.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.86 | 1.74 | 3.51 | 4.14 | 3.75 |